Full-Time

Sr Manager – Validation and Change Lead

Posted on 8/29/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Engineering Management (3)
, ,
Requirements
  • Doctorate degree / Master's degree / Bachelor's degree and 12 to 17 years Product Owner / Platform Owner / Service Owner
  • Strong knowledge of Agile methodologies, CSV Validation and Automated Testing.
  • Exceptional collaboration, communication and interpersonal skills to effectively manage collaborator relationships and build new partnerships.
  • Have strong business acumen. Can demonstrate deep understanding business processes in a biotechnology environment.
  • Familiarity with Resourceful Automation with experience in automations tools like UiPath & Power Automate, Process Intelligence tools like Celonis, DocuSign and GenAI Tools/LLMs.
  • Proven ability to lead multidisciplinary teams including analysts, engineers, and architects in a matrixed and agile environment.
Responsibilities
  • Maintain strategic relationships and strong communication with the leadership team about IS services and service roadmaps to ensure that all the collaborators feel informed and engaged
  • Lead and manage large, diverse teams within a matrixed organization.
  • Serve as Scrum Master for Cross-Functional Agile teams, leading sprint planning, daily stand-ups, retrospectives, and backlog grooming to ensure timely delivery of automation and AI solutions.
  • Act as a servant leader by identifying and removing roadblocks, promoting Agile best practices, and fostering a culture of continuous improvement and team empowerment within the AI & Automation delivery squads.
  • Define, implement, and oversee computer system validation strategies aligned with regulatory requirements (e.g., FDA 21 CFR Part 11, EU Annex 11) for GxP-relevant systems used across R&D, manufacturing, and quality operations.
  • Collaborate with automation, IT, and quality teams to validate AI/ML-enabled systems and intelligent automation tools, ensuring their lifecycle management meets CSV and data integrity standards.
  • Serve as CSV subject matter expert (SME) during internal and external audits or health authority inspections, providing defensible validation documentation and training Cross-Functional collaborators.
  • Collaborate with geographically dispersed teams, including those in the US and other international locations.
  • Attract and recruit top talent as part of an extensive AI & Technology organization to be hired within India.
  • Responsible for managing, growing, and developing the Amgen Technology team in India, ensuring global ways of working are imbedded in the local organization
  • Understand the decision-making process, workflows, and business and information needs of business partners and collaborators
  • Improve activities being measured by crafting, monitoring, and optimizing relevant feedback loops through 'test & learn' activities
  • Work with Product Owners, Service Owners and/or delivery teams to ensure that delivery matches commitments, acting as a partner concern point and facilitating communication when service commitments are not met
  • Ensure communication of key performance metrics and analysis of unmet needs
  • Participate in collaborator and other leadership meetings, working with other parts of the organization, and functional groups to ensure successful delivery
  • Facilitate standard methodology sharing, ensuring ongoing alignment with the Technology & Digital strategy
  • Oversee operating budgets and product team budgets, ensuring regular review of actuals and latest estimates, managing according to agreed governance
Desired Qualifications
  • Experience in a leadership role within a pharmaceutical or technology organization
  • Extensive experience in software development lifecycle.
  • Experience using and adoption of Scaled Agile Framework (SAFe)
  • Strong analytic/critical-thinking and decision-making abilities.
  • Ability to work effectively in a fast-paced, dynamic environment.
  • Established business partnerships and IS governance practices involving senior business collaborators
  • Broad working knowledge of key AI, Intelligent Automation, IS and Business domains
  • Familiarity with regulations (e.g., FDA 21 CFR Part 11, EU Annex 11) and risk-based validation
  • Computer System Validation Professional (CSV) Certification (preferred)
  • Certified ScrumMaster (CSM) or SAFe Scrum Master (SSM) (preferred)
  • Project Management Professional (PMP) (preferred)
  • Excellent leadership and team management skills.
  • Strong transformation and change management experience.
  • Exceptional collaboration and communication skills.
  • High degree of initiative and self-motivation.
  • Ability to manage multiple priorities successfully.
  • Team-oriented with a focus on achieving team goals.
  • Strong presentation and public speaking skills.
  • Excellent analytical and troubleshooting skills
  • Strong verbal and written communication skills
  • Ability to work effectively with global, virtual teams
  • Regulatory Writing: Ability to write clear, audit-ready documentation and validation reports.
  • Leadership: Leading validation teams, mentoring junior staff, driving validation strategy.
  • Analytical Thinking: Ability to troubleshoot issues and apply critical thinking to problem-solving.
  • Attention to Detail: High standards for compliance, documentation accuracy, and traceability.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE